RE: Science Questions17 May 2020 14:06
"In April, Tiziana filed a patent application for the combination of anti-IL-6R with nanoparticle-Actinomycin D (NP-ACT D) in treating severe COVID-19 cases.
Patients with severe symptoms could feel “immediate relief” as the antiviral drug (NP-ACT D) stops the virus from expanding, while the anti-inflammatory agent (anti-IL-6R) suppresses a possible 'cytokine storm'.
A 'cytokine storm' is an uncontrolled immune response resulting in excessive production of substances believed to be associated with severe lung damage, commonly observed in coronavirus patients."